Floatz logo

Anti-Cd19 Anti-Cd20 Bispecific Car-T

Lymphoma

Beijing Doing Biomedical Co., Ltd.Cell therapyPhase 1Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

289 Active assets in the Lymphoma cohort.

Asset / SponsorPhaseRating
VINBLASTINE
Intensity Therapeutics, Inc.
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
The Lymphoma Academic Research Organisation
Phase 4BBB
BLEOMYCIN
Shandong Provincial Hospital
Phase 4BB
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
(+)-VINCRISTINE
Beth Israel Deaconess Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Anti-Cd19 Anti-Cd20 Bispecific Car-T is also rated in:

B-cell acute lymphoblastic leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
RefractoryDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →